Abstract
Hodgkin lymphoma (HL) and diffuse large B cell lymphoma (DLBCL) represent 15% and 20%, respectively, of all lymphoma types. The aim of this study was to identify and compare circulating serum miRNA (c-miRNA) and peripheral whole blood miRNA (wb-miRNA) profiles in patients with these lymphomas. Serum samples (20 HL, 21 DLBCL, and 30 healthy controls) and whole blood samples (21 HL, 17 DLBCL patients, and 30 healthy controls) were collected at the time of diagnosis. Serum and whole blood were also collected from 18 HL/17 DLBCL and eight HL/nine DLBCL patients, respectively, after treatment. Pairwise comparisons identified 125 c-miRNAs (adjusted P value < 0.05) showing significant dysregulation between 30 healthy controls and patients; of these, 47 and 55 differentiated controls from pretherapeutic HL and DLBCL patients, respectively. In addition, 60 and 16 c-miRNAs differentiated controls from posttherapeutic HL and DLBCL, respectively. Pairwise comparisons identified 292 wb-miRNAs (adjusted P value < 0.05) showing significant dysregulation between 30 controls and patients; of these, 103 and 169 differentiated controls from pretherapeutic HL and DLBCL, respectively, and 142 and 151 wb-miRNAs differentiated controls from posttherapeutic HL and DLBCL, respectively. Thus, lymphoma-associated miRNAs may be a better source of noninvasive candidate biomarkers than miRNAs in serum. It is unclear whether miRNA alterations in lymphoma cells are similar to those observed in white blood cells.
Highlights
Lymphomas are a heterogeneous group of malignances that arise from B or T cells; they show varying genetics, pathogenesis, clinical presentations, and responses to treatment, resulting in variable outcomes [1,2,3]
Hodgkin lymphoma (HL), in which tumor cells constitute less than 1% of the tumor bulk [1, 4], is one of BioMed Research International
The cohort no. 1 included patients with classical HL and diffuse large B cell lymphoma (DLBCL) patients whose serum samples were collected progressively; the cohort no. 2 included 23 HL and 20 DLBCL whose peripheral blood samples were already deposited at the institutional biobank (Table 1)
Summary
Lymphomas are a heterogeneous group of malignances that arise from B or T cells; they show varying genetics, pathogenesis, clinical presentations, and responses to treatment, resulting in variable outcomes (even among patients with a similar diagnosis) [1,2,3]. There are more than 100 different lymphoma types, most are B cell lymphomas [4]. Hodgkin lymphoma (HL), in which tumor cells constitute less than 1% of the tumor bulk [1, 4], is one of BioMed Research International COHORT 1 DLBCL, n = 21 HL, n = 20. 5 (24%) 31 (23–68) CS III/IV 13 (62%)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have